

## **Molecular Pharmacology**


### **Antileukemic activity and mechanism of drug resistance to the marine *Salinispora tropica* proteasome inhibitor salinosporamide A (marizomib)**

Denise Niewerth, Gerrit Jansen, Lesley F.V. Riethoff, Johan van Meerloo,  
Andrew J. Kale, Bradley S. Moore, Yehuda G. Assaraf, Janet L. Anderl, Sonja  
Zweegman, Gertjan J.L. Kaspers, and Jacqueline Cloos


## Supplemental figures

**Figure S1. Impact of salinosporamide A compared to bortezomib on proteasome catalytic activity in parental and bortezomib-resistant CEM cells.** Chymotrypsin-like, caspase-like, and trypsin-like proteasome activity was analyzed by Proteasome-Glo assay in intact (**A**) parental CEM/WT cells, and (**B**) bortezomib-resistant CEM/BTZ200 cells after 1-hour exposure to salinosporamide A (Sal A) or bortezomib (BTZ). Results are presented relative to untreated controls and represent the mean ( $\pm$  standard deviation) of three independent experiments.

**Figure S1**



**Figure S2. Impact of salinosporamide A on proteasome catalytic activity in parental and bortezomib-resistant CEM cells.**  $\beta 5$ ,  $\beta 5i$ , and  $\beta 1i$ -associated catalytic activity in cell extracts of CEM/WT, CEM/BTZ7, and CEM/BTZ200 cells was assessed after 1-hour exposure to salinosporamide A. Results depicted represent the mean ( $\pm$  standard deviation) of 3 separate experiments.



**Figure S3. Accumulation of ubiquitinated proteins in parental CEM and salinosporamide A-resistant CEM cells after salinosporamide A exposure.** Western blot analysis of accumulation of polyubiquitinated proteins in untreated cells, after 24h exposure to salinosporamide A (10 nM for CEM/WT, 30 nM and 60 nM for CEM/S30).

